Comparison · NCT02454283-13ffd01b
Vanoxerine HCl vs Placebo: Conversion to Sinus Rhythm
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vanoxerine HCl vs Placebo: Conversion to Sinus Rhythm. Trial comparisons, record NCT02454283-13ffd01b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02454283-13ffd01b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.692 | 0.5 | 0.835 | wilson | |
| Risk in group 2 | 0.2 | 0.0705 | 0.452 | wilson | |
| Risk difference, group 1 minus group 2 | 0.492 | 0.175 | 0.685 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.46 | 1.22 | 9.83 | log | |
| Odds ratio, group 1 over group 2 | 9 | 1.98 | 40.9 | log | |
| Number needed to treat, for one more participant with the outcome on Vanoxerine HCl than on Placebo | 2.03 | 1.46 | 5.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vanoxerine HCl | Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose~Vanoxerine HCl | 18 | 26 | OG000 |
| Group 2 | Placebo | identically matching placebo capsules, orally, single-dose~Placebo | 3 | 15 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Conversion to Sinus Rhythm
- Description
Conversion to sinus rhythm (or atrial paced rhythm in the case of subjects with a pacemaker and atrial leads) documented by ECG (Holter ECG, 12-lead ECG, monitor lead ECG, or other format ECG) of at least 1 continuous minute within the 24 hours defined by the time of study drug administration through 24 hours after the time of study drug administration.
- Time frame
- 24 hours
- Population
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
- NCT number
- NCT02454283
- Phases
- PHASE3
- Conditions
- Atrial Fibrillation or Flutter
- Interventions
- Vanoxerine HCl, Placebo
- Lead sponsor
- Laguna Pharmaceuticals, Inc.
- Results first posted
- 2016-10-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02454283?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02454283-13ffd01b